A methodology is proposed, based on Raman spectroscopy coupled with multivariate analysis, to determine the Limit of Detection (LOD) and Limit of Quantification (LOQ) for therapeutic drug monitoring in human serum, using the examples of Busulfan, a cell cycle non-specific alkylating antineoplastic agent, and, Methotrexate, a chemotherapeutic agent and immune system suppressant. In this study, ultrafiltration is employed to fractionate spiked human pooled serum to efficiently recover the drug in the filtrate prior to performing Raman analysis.
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Drishya Parachalil, Franck Bonnier, Deirdre Commerford, Igor Chourpa, Jennifer McIntyre, and Hugh J. Byrne This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/nanolart/88 Introduction Therapeutic drug monitoring (TDM) refers to the clinical practice of management of a patient's drug dosage within a targeted therapeutic window, based on measurement of concentration of the drug in the bloodstream at timed intervals. For drugs with a narrow therapeutic range, such monitoring is essential to provide individualised patient treatment, while maintaining the efficacy of drugs and minimising drug toxicity and related adverse effects (1, 2) . TDM has also been increasingly advocated to improve the standard of chemotherapy, in which side effects can be substantial and life threatening (3) (4) (5) (6) . The currently available technique of chemotherapeutic-dosage calculation based on dose intensity and body surface area has been reported to be inaccurate for patients undergoing sustained chemotherapeutic treatment (7, 8) .
In the era of rising cost of healthcare, it is necessary to develop a rapid, sensitive, and costeffective, point-of-care technique for TDM, which can quantitatively measure the serum concentration of drugs, such that the dosing strategy can be tailored to the metabolism of an individual patient for a personalised therapeutic regime.
Busulfan (Bu) is a bi-functional alkylating agent (see chemical structure in inset of Figure 2A) used in the chemotherapy-based conditioning regimen for hematopoietic stem cell transplantation (HSCT) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Bu has a very narrow therapeutic index, and higher systemic exposure to Bu is related to hepatic sinusoidal obstruction syndrome, neurotoxicity or insterstitial pneumonia, while low levels have been shown to be associated with increased incidence of graft rejection (18-21). Measurement of individual serum Bu levels during oral or intravenous dosing is likely to provide the necessary elements to monitor the drug disposition, ensuring efficacy, reduced incidences of toxicity and graft rejection (18-22). Several analytical methods, including chromatographic techniques coupled with a number of detection methods, have been described for analysing Bu in biological fluids; Gas chromatography (GC) with electron capture detection, high performance liquid chromatography (HPLC) with UV detection, GC-Mass spectroscopy (MS) with selected ion monitoring, and Enzyme linked immunosorbent assays (ELISA) have been reported to have high sensitivity for monitoring Bu in biological fluids (10, 11, (23) (24) (25) (26) . However, the translation of these techniques to a routine analytical tool in a clinical setting for TDM is impractical, owing to their complexity and cost.
Methotrexate (MTX) is a folate antagonist (see chemical structure in the inset of Figure 2B) widely used as an anti-cancer agent to treat various malignancies, such as leukemia, breast cancer, lymphomas and autoimmune diseases (27) . MTX is administered in both low and high dosage (LDMTX and HDMTX), and monitoring serum MTX concentrations is essential to avoid high dosage related side effects (28) . Serum MTX concentrations can vary from 10 nM to 1 mM for different patients, due to pharmacokinetic variability (28) . The serum MTX concentration should reach between 10µM (0.001mM) and 100µM (0.01mM) after 12-36 hours of HDMTX infusion and should reduce to 0.2µM after 72 hours. From the clinical point of view, it is essential to be able to detect the serum concentrations of MTX between 0.1µM and 10µM, as high toxicity related adverse effects are associated with concentrations >10µM (28, 29) . Various sophisticated analytical tools such as Enzyme multiplied immunoassay technique (30) , radioimmunoassay (31), enzyme exhibition assays (32), capillary zone electrophoresis (33) and liquid chromatography coupled with tandem mass chromatography (HPLC-MS/MS) (6, (34) (35) (36) (37) (38) (39) have been reported for TDM of MTX from biological fluids.
Although immunoassays (40) and separation techniques (38) are routinely employed due to, they suffer from major limitations such as interferences from other compounds and lack of availability for all the drugs currently monitored (4). HPLC-MS/MS is considered the gold standard method for MTX (35) (36) (37) (38) (39) analysis due to its high sensitivity and robustness; however, it is time consuming, expensive and requires skilled personnel.
In recent years, Surface enhanced Raman spectroscopy (SERS) has been reported to be a good candidate for TDM of MTX (28, 29, 41) , doxorubicin (42) , paclitaxel and cyclophosphamide (3) in biological fluids, since quantitative analysis of drugs can be performed rapidly and higher sensitivity. By comparison, quantification of Bu in biological fluids using spectroscopic techniques has not been explored. Critical issues of using SERS for TDM include development of standardised substrates, intense surface enhanced resonance SERS responses from other biological molecules such as carotenoids and also the spectral interference from the fluorescence that could interfere with the drug detection (28, 43) . Therefore, new techniques that are inexpensive, less complex and faster are essential to quantitatively determine the concentration of drugs in a clinical setting. Herein, a rapid drug screening strategy using Raman spectroscopy coupled with ultrafiltration and multivariate analysis technique for Bu and MTX from liquid serum that yields a significant improvement in detection capabilities and minimises error is explored.
Materials and Methods

Materials
Methotrexate (A6770), Busulfan (B058) and human pooled serum (H6194) were purchased from Sigma Aldrich, Ireland. Stock solutions of 0.1mg/mL Bu in methanol and 1mM MTX in 0.1M NaOH were prepared. The spiked concentrations of Bu in serum are expressed in mg/mL and MTX in µM to be consistent with previous studies (4, 29) . The commercial human serum was spiked with Bu and MTX over the therapeutically relevant concentration ranges, to achieve the final concentrations of (0 -0.05 mg/mL) for Bu and (0 -100 µM) for MTX. The normal therapeutic range for Bu is 0.0005mg/mL to 0.005mg/mL and any concentration below 0.0005mg/mL can cause transplant failure, or higher than 0.005mg/mL, transplant related mortality (11), whereas for MTX, 1µM to 10µM and <10µM is considered toxic (29) . Raman spectra of highly concentrated Bu and MTX drug solutions prepared with a minimal amount of water (~1mg/mL) are used as the reference for the Extended Multiplicative Signal Correction algorithm (see Data pre-processing and analysis ).
Amicon Ultra 0.5mL centrifugal filter devices (Millipore-Merck, Germany), with a cut off point of 10kDa, were employed to fractionate the serum samples. The centrifugation procedure previously reported by Bonnier et al. was followed (44) . The optimised washing and rinsing procedure includes spinning 0.5mL 0.1M NaOH at 14000×g for 30 minutes, followed by three rinses with distilled water by spinning 0.5mL distilled water for 30 minutes at 14000×g. Every 30 minute wash and rinse must be followed by spinning the device in the inverted position at 1000×g for 2 minutes, to remove the residual solution contained in the filter. After washing, 0.5mL of spiked serum solution is transferred to the 10kDa filter and centrifuged at 14000×g for 30 minutes. The filtrate that passes through the 10kDa filter contains mostly water and molecules smaller than 10kDa. All the filtrate solutions were analysed using Raman spectroscopy and five replicate measurements from different positions have been recorded. In subsequent analysis, each dosed serum sample is represented by all the spectra recorded from that sample, rather than the mean.
Raman spectroscopy
The measurement conditions used for screening analytes in human serum in the liquid form have recently been detailed (45, 46) . Raman spectra of all the liquid serum filtrate samples and references were recorded at stabilised room temperature (18ºC) using a Horiba Jobin-Yvon LabRam HR800 spectrometer with a 16-bit dynamic range Peltier cooled CCD detector. A 532nm laser was used, which had a power of ~30 mW at the sample, with a 600 lines/mm grating and the backscattered Raman signal was integrated for 3×80 seconds over the spectral range from 400-1800 cm -1 . The spectrometer was coupled to an Olympus 1X71 inverted microscope and a x60 water immersion objective (LUMPlanF1, Olympus) was employed. The substrate used was a Lab-Tek plate (154534) with a 0.16-0.19mm thick, 1.0 borosilicate glass bottom, and was purchased from Thermo Fischer Scientific, Ireland.
Data pre-processing and analysis
The raw spectra were subjected to pre-processing techniques in Matlab before further analysis, to remove the background signal and reduce the noise. Smoothing of the raw data was done using the Savitzky-Golay method (polynomial order of 5 and window 13) and the rubberband method (45) was found to be appropriate to baseline correct the smoothed reference spectra of both the drugs. The 'rubberband' correction was carried out by wrapping a 'rubberband' of defined length around the ends of the spectrum to be corrected and fitting against the curved profile of the spectrum. An adapted Extended Multiplicative Signal Correction (EMSC) algorithm (47) , with a 3rd order polynomial, was applied to remove the underlying water spectrum from all the dataset, whose OH bending feature at 1640 cm -1 can interfere with the analyte spectra, and also scales the analyte spectra, assuming a constant water contribution to all sample spectra (47) .
Partial Least Squares Regression
Partial Least Squares Regression (PLSR) was employed to establish a model that relates the variations of the spectral data to a series of concentrations. This regression model can be used to establish the limit of detection and quantitation of Raman bio-sensing of drugs (48, 49) .
Constructed based on the spectra of samples of known drug content, over a range of varying concentrations of drug (in commercial serum), the model is then validated using a rigorous cross validation procedure which evaluates its performance in accurately predicting drug concentrations. For consistency with previous studies (45, 46) , a 20 fold cross validation approach has been employed to validate the robustness of the method. This approach involves randomly dividing the set of observations into approximately equal size, 50% of the spectral data were randomly selected as test set, while the remaining 50% is used as the training set (50) . The cross-validation process is then repeated 20 times (the folds), whereby all observations are used for both training and testing, and each observation is used for testing exactly once. The results from the folds can then be averaged to produce a single estimation.
The Root Mean Square Error of Cross Validation (RMSECV) is calculated from the 20 iterations to measure the performance of the model for the unknown cases within the calibration set. The correlation between the true and predicted concentrations is given by the R 2 value. The standard deviation was calculated to quantify the amount of variation in the dataset. The number of latent variables used for building the PLSR model is optimised by finding the value that is equivalent to the minimum of the RMSECV. The Limit of Detection (LOD) and Limit of Quantification (LOQ) of these two drugs for this method were calculated from the PLSR prediction plot, using a IUPAC-consistent approach previously reported for multivariate regression analysis by Ostra et al. (48) .
where, Sblank is the standard deviation of a blank (zero concentration sample) and b is the slope of the regression (inverse calibration) model, in the region of linearity. The slope was calculated for the linear region of the prediction plot, including the standard deviation of each point, by initially regressing over the higher concentrations, and progressively adding smaller concentrations to the regression range, until the calculated slopes were seen to begin to reduce. The advantages of employing an inverted geometry to record Raman spectra have been detailed by Bonnier et al (51) . The feasibility of using a Lab-Tek plate as substrate (45) and impact of ultra-filtration coupled with multivariate analysis techniques in detecting low molecular weight fraction analytes have also previously been reported (46, 52, 53) . The Raman spectra recorded from the 10kDa filtrate of Bu and MTX spiked serum samples were subjected to pre-processing steps followed by PLSR analysis. The whole finger print region (400-1800cm -1 ) was chosen to build PLSR prediction for Bu, whereas a shorter region, in which there are strong bands of MTX (1200-1800cm -1 ), was chosen to facilitate efficient prediction of MTX by increasing the sensitivity. The improvement of the sensitivity of the prediction model for the case of glucose and urea when regressed over a reduced spectral region was previously reported (46, 54) . The normal and toxic ranges of the Bu and MTX were encompassed by the range of spiked serum samples. RMSECV were calculated to be 0.0003mg/mL for Bu and 4.02 µM for MTX, respectively Figure 2A shows the reference spectrum of Bu, and the signature peaks of Bu at 1097cm -1 and 1453cm -1 , which can be ascribed to a CH2 scissoring mode and C-C stretching, respectively (55) . In the case of MTX, the signature peaks are a strong band at 1593cm -1 , which can be ascribed to the scissoring of the NH2 group, while the sharp band at 1351cm -1 can be ascribed to CH2 scissoring vibrations ( Figure 2B) (4,29,41) . The pre-processed data set of systematically varied concentration of spiked, filtered serum ( Figure S1A and B) is fed into the PLSR algorithm to build a prediction model that correlates the known concentration and the predicted concentration, based on the variation in spectral intensity, for each drug. On the basis of the A C D A B percent variance explained by the latent variables and the lowest value of RMSECV, the total number of latent variables used to reach the best performance is calculated to be 3 for both Bu and MTX ( Figure S3A and B) . The RMSECV values are calculated to be 0.0003mg/mL for Bu and 4.02µM for MTX. The PLSR coefficient plots ( Figure 2C and D) of Bu and MTX display Raman bands in good accordance with the reference ones, namely, the presence of peaks at 1097cm -1 and 1453cm -1 for Bu, and 1593cm -1, and 1351cm -1 for MTX, respectively. Figure S2A and B show that the signature peaks of Bu and MTX are discernible at the detection of limits identified by the respective PLSR models. Samples with Bu concentrations higher than 0.002mg/mL are frequently observed in many hospitals, but, Bu concentrations less than 0.0005mg/mL are rarely seen (11) . This Raman spectral response was validated to be linear over the entire range of 0.0003mg/mL to 0.0125mg/mL, which has not been fully validated in previous studies. In comparison to the earlier studies based on LC-MS, the present method shows similar performances in precision and recovery (13, 16, 24, 56) . However, considering the time needed for sample preparation for the chromatography based methods, the present method has an added advantage that it does not require complex sample preparation steps. Besides, the amount of sample required for this method (1-50 μL) is slightly less than that for other commonly employed methods (50 to 200 μL) (11) . Thus, this proposed approach can be expeditiously implemented in laboratories in clinical settings for introduction of TDM (4, 29, 57, 58) . For most drugs, the process of drug elimination is a firstorder rate process, and so, in a given patient, can be characterised by a rate constant (59) .
Results and Discussion
Therefore, from the clinical point of view, regular monitoring of MTX levels in patient serum can be used to determine a rate of drug elimination and help establish a personalised dosing regime for each patient. In previous studies, many researchers have reported the use of SERS substrates to detect MTX in plasma/serum with a LOD as low as 0.17μM (29) . Although SERS gives promising results in detecting drugs at low concentrations in biological matrices (28, 29) , qualitative variations within the SERS substrate (60) , the interference of other biomolecules with the SERS spectra, makes quantification in real samples a challenging task (43) .
Alternatively, Bonifacio et al. demonstrated the use of Ag and Au colloids as SERS substrates to obtain intense and repeatable spectra from serum filtrate (61) .
In contrast, the proposed method with inverted Raman spectroscopy is cost-effective and easy to use, that can be translated as a point-of-care diagnostic tool for high-dosage MTX in bodily fluids. Notably, in determining the LOD and LOQ, while the slope of the concentration dependent response is dependent on the Raman scattering cross section of the analyte, the standard deviation of the blank is a measurement parameter, and instrument specific, and could potentially be improved by reduced noise and/or signal variability.
Conclusion
In summary, a rapid, sensitive, cost effective and reproducible method to determine the Bu and 
